Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
In this video we present the ex vivo generation and expansion of human CD40-activated B cells (CD40-B) from peripheral blood mononuclear cells (PBMC) by stimulation with CD40 ligand and interleukin-4.
CD40-activated B cells (CD40-B cells) have been identified as an alternative source of immuno-stimulatory antigen-presenting cells (APC) for cancer immunotherapy 1-3. Compared to Dendritic cells (DCs), the best characterized APC, CD40-B cells have several distinct biological and technical properties. Similar to DCs, B cells show an increased expression of MHC and co-stimulatory molecules (Fig.1b), exhibit a strong migratory capacity and present antigen presentation efficiently to T cells, after stimulation with interleukin-4 and CD40 ligand (CD40L). However, in contrast to immature or mature DCs, CD40-B cells express the full lymph node homing triad consisting of CD62L, CCR7/CXCR4, and leukocyte function antigen-1 (LFA1, CD11a/CD18), necessary for homing to secondary lymphoid organs (Fig.1a) 3. CD40-B cells can be generated without difficulties from very small amounts of peripheral blood which can be further expanded in vitro to very large amounts of highly-pure CD40-B cells (>109 cells per patient) from healthy donors as well as cancer patients (Fig.1c,d) 1,4.
In this protocol we demonstrate how to obtain fully activated CD40-B cells from human PBMC. Key molecules for the cell culture are CD40 ligand, interleukin-4 (IL-4) and cyclosporin A (CsA), which are replenished in a 3-4 day culture cycle. For laboratory purposes CD40-stimulation is provided by NIH/3T3 cells expressing recombinant human CD40 ligand (tCD40L NIH/3T3) 5. To avoid contamination with non-transfected cells, expression of the human CD40 ligand on the transfectants has to be checked regularly (Fig.2).
After 14 days CD40-B cell cultures consist of more than 95% pure B cells and an expansion of CD40-B cells over 65 days is frequently possible without any loss of function 1, 4. CD40-B cells efficiently take up, process and present antigens to T cells 6. They do not only prime naϊve, but also expand memory T cells 7,8. CD40-activated B cells can be used to study B-cell activation, differentiation and function. Moreover, they represent a promising tool for therapeutic or preventive vaccination against tumors 9.
The protocol for the generation of human CD40-activated B cells from PBMC is divided into two parts: Part A demonstrates the preparation of CD40 ligand expressing NIH/3T3 cells, which will be used as plate-bound feeder cells. Part B describes the actual CD40-B culture.
A. Preparation of feeder cells (tCD40L NIH/3T3)
The tCD40L NIH/3T3 is an adherent murine fibroblast cell line, which should never become completely confluent. The cells are therefore splitted twice per week. Culturing over more than 6 weeks is not recommended.
B. CD40-B cell culture
I. Preparation of PBMCs for CD40-stimulation (day 0):
Please note: before you continue ascertain that feeder cells are adherent. Always add fresh solutions of interleukin-4 and cyclosporin A to the growth medium immediately before use.
II. Recultivation of CD40-B cells (day 7 and then every 3-4 days):
C. Trouble-shooting – What if CD40-B cells do not grow?
Figure 1. Please click here for a larger version of figure 1.
Figure 2. Please click here for a larger version of figure 2.
Access restricted. Please log in or start a trial to view this content.
Name | Company | Catalog Number | Comments |
A. Preparation of Media: | |||
1. Feeder cell wild type medium | |||
DMEM-Ham’s / F12 | |||
L-Glutamine (365 μg/mL) | |||
FBS (10%) | |||
HEPES (10 mM) | |||
Gentamycin (15 μg/mL) | |||
2. Feeder cell selection medium | |||
DMEM-Ham’s / F12 | |||
L-Glutamine (365 μg/mL) | |||
FBS (10%) | |||
HEPES (10 mM) | |||
Gentamycin (15 μg/mL) | |||
G-418 (0.7 mg/mL) | |||
3. CD40-B washing medium | |||
IMDM | |||
L-Glutamine (584 μg/mL) | |||
HEPES (25 mM) | |||
Gentamycin (15 μg/mL) | |||
4. CD40-B culture medium | |||
IMDM | |||
L-Glutamine (584 μg/mL) | |||
HEPES (25 mM) | |||
Gentamycin (15 μg/mL) | |||
rh Transferrin (50 μg/mL) | |||
rh Insulin (5 μg/mL) | |||
AB-Humanserum (10%) | |||
B. Miscellaneous Reagents: | |||
DMEM / Ham’s F12 | PAA Laboratories | Cat No: E15-813 | |
IMDM | Invitrogen | REF 21980-032 | |
Dulbecco’s PBS (10x) | PAA Laboratories | Cat No H15-011 | |
AB-Human Serum | Invitrogen | Cat No 34005100 | |
holo-Transferrin human | Sigma-Aldrich | Cat No T0665 | |
Insulin human | Sigma-Aldrich | Cat No I2643 | |
Gencin® | Delta Select | Art No 7395800 | |
Recombinant Human Interleukin-4 | Immunotools | Cat No 11130045 | |
Cyclosporin A | Novartis AG | Cat No NDC 0078-0109-01 | |
FBS | Lonza Inc. | Cat No DE14-802C | |
HEPES Buffer | PAA Laboratories | Cat No S11-001 | |
G-418 Sulphate | PAA Laboratories | Cat No P02-012 | |
Trypsin/EDTA (10x) | Invitrogen | REF 15400-054 | |
C. Miscellaneous Supplies: | |||
Sterile pipette tips | Sarstedt Ltd | ||
6-well plate | Nalge Nunc international | Cat No 140675 | |
50mL conical tube | BD Biosciences | Cat No 352070 | |
Tissue culture flask | Sarstedt Ltd | Cat No 83.1813.002 |
Access restricted. Please log in or start a trial to view this content.
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone